Søren Echwald has been named CEO at Anapa Biotech. The Danish biotech, previously called QuantiBact, is developing molecular tools to enhance the performance of natural nucleic acids in PCR and hybridization-based assays.

Echwald joins Anapa from Exiqon, where he was vice president of business development. He takes over the CEO position from Palle Schelde, who has left the company to pursue other opportunities in the biotech industry, Anapa said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.